Hans Kwaku, MD
Internal Medicine · Charlotte, NCNPI 1689630691
Payments from drug & device makers
Across 566 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- Lilly USA, LLC$896
- Boehringer Ingelheim$715
- Johnson & Johnson$643
- Sanofi-aventis U.S. LLC$633
- plus $4K from 29 others
What the payments were for
- Food & beverage$10,505100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 93 | $1,859 |
| AstraZeneca | 91 | $1,475 |
| Lilly USA, LLC | 51 | $896 |
| Boehringer Ingelheim | 40 | $715 |
| Johnson & Johnson | 28 | $643 |
| Sanofi-aventis U.S. LLC | 33 | $633 |
| AbbVie | 24 | $562 |
| Pfizer | 28 | $496 |
| Bayer | 26 | $395 |
| GSK | 25 | $393 |
| Amgen(2 entities) | 21 | $382 |
| Merck | 14 | $219 |
| Kowa Pharmaceuticals America, Inc. | 15 | $216 |
| Novartis | 11 | $168 |
| Amarin Pharma, Inc. | 10 | $150 |
| Hologic Sales And Service, LLC | 1 | $141 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $139 |
| Hikma Pharmaceuticals USA | 9 | $131 |
| Idorsia Pharmaceuticals US Inc | 1 | $122 |
| E.r. Squibb & Sons, L.L.C. | 7 | $120 |
| Mayne Pharma Commercial LLC | 1 | $114 |
| Abbott | 5 | $112 |
| Astellas Pharma US Inc | 3 | $69 |
| Shield Therapeutics Inc | 3 | $54 |
| Exact Sciences | 3 | $53 |
| Corcept Therapeutics | 3 | $47 |
| Xeris Pharmaceuticals, Inc. | 3 | $46 |
| Nevro Corp. | 2 | $32 |
| Vifor Pharma, Inc. | 1 | $28 |
| Oxford Immunotec USA Inc | 1 | $21 |
| Mannkind Corporation | 1 | $18 |
| Global Blood Therapeutics, Inc. | 1 | $17 |
| Bioventus LLC | 1 | $17 |
| Sanofi | 1 | $14 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,511 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $66,826 |
| TrulicityDulaglutide | 20 | $23,954 |
| MounjaroTirzepatide | 13 | $18,384 |
| JanuviaSitagliptin Phosphate | 23 | $14,675 |
| EliquisApixaban | 15 | $14,250 |
| FarxigaDapagliflozin Propanediol | 22 | $13,641 |
| LinzessLinaclotide | 20 | $12,514 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $11,149 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $9,671 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,850 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $6,678 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,134 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 85 | $2,116 |
| Omeprazole | 132 | $1,996 |
| Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide | 60 | $1,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,859 | $66,82666 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $896 | $42,33933 claims |
| AstraZenecaFarxiga, Symbicort | $1,475 | $20,31935 claims |
| MerckJanuvia | $219 | $14,67523 claims |
| PfizerEliquis | $496 | $14,25015 claims |
| AbbVieLinzess | $562 | $12,51420 claims |
| GSKTrelegy Ellipta | $393 | $8,85012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Charlotte
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- Lyndsay MolinariCharlotte$2.4M
- Claud GriggCharlotte$1.5M
- Maher AghaCharlotte$1M
- Jonathan SchwartzCharlotte$824K
- Marc JohnsonCharlotte$823K
- Santosh GopalakrishnanCharlotte$598K
- Maithili ChitnavisCharlotte$536K
- Christopher FerreriCharlotte$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.